To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of ribociclib (LEE011, Kisqali) in hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer.
Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients / Rascon, K.; Flajc, G.; De Angelis, C.; Liu, X.; Trivedi, M. V.; Ekinci, E.. - In: THE ANNALS OF PHARMACOTHERAPY. - ISSN 1060-0280. - 53:5(2019), pp. 501-509. [10.1177/1060028018817904]
Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients
De Angelis C.;
2019
Abstract
To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of ribociclib (LEE011, Kisqali) in hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
